NEPAL EXPANSION · KATHMANDU VALLEY
Building a Scalable Preventive Healthcare Platform with Strong Recurring Revenue
Kathmandu · Patan (Lalitpur) · Bhaktapur
Strategic Investment Opportunity for Nepali Investors · 2026
Investment Case · Evidence First
NanoChain Nepal — Staged Investor Case 2026
The investment case is presented below as an evidence-gated path from paid pilot to dense Valley clusters, renewal proof and controlled replication.
Deep Dive · Market Research
Nepal Market Research & Feasibility Paper 2026
The evidence behind the deck: census-based market sizing for Kathmandu, Patan and Bhaktapur, competitor pricing in the Valley, regulatory requirements, a full audit of the financial model with every open assumption listed, and a diligence checklist for investors.
Word format, about 22 pages. Modelled figures are labelled as projections, not commitments.
Investor Inquiry
Talk to the founder team
Interested in participating? Share a few details and we'll follow up with the data room, terms and a call.
Investor Q&A
Ask the deck
Have a question about unit economics, pilot gates, the Valley rollout or lessons from the predecessor operation? Our AI-powered assistant answers using only what's in the investor materials, and tells you when something isn't covered.
Your conversation is saved in this browser only.
Executive Summary
Our Investment Proposition
NanoChain is a Nepal-first preventive diagnostics venture designed to test, validate and scale across the three historic cities of the Kathmandu Valley.
The Opportunity
Nepal's Diagnostics Market
Large Out-of-Pocket Spend, Fragmented Supply, Transaction-Led
- Diagnostics in Nepal is overwhelmingly paid out-of-pocket, one test at a time
- Valley labs compete on price, not on patient relationship or retention
- No meaningful annual membership or preventive-care product in the market
- Low lifetime value and no recurring revenue visibility for incumbents
- Rising chronic disease burden in urban Nepal with almost no structured monitoring
- Growing insurance and corporate wellness demand with no organised diagnostics partner
We replace one-time pathology dependency with an annual subscription model.
Case Study 01 · Lessons
What the predecessor operation taught us
Product interest was demonstrated, but the financial model was not a profitable benchmark.
Management-supplied audit summary; figures require source-statement verification during diligence. Indian Rupees.
Demand existed, but peak sales did not prove durable profitability
A 51.9% decline from peak exposed channel concentration
High-cost borrowing and fixed overhead weakened resilience
NanoChain does not inherit a profitability claim. It inherits operating lessons: protect route density, define benefits, contract institutional volume and release equity capital only after evidence.
NanoChain Case Studies
Proof will be built in Nepal
Each stage answers one investor question before the next capital tranche is released.
Test channel conversion, utilization, direct contribution, service quality and willingness to renew.
Prove collections per shift, turnaround time, failed-visit rate and route-level contribution.
Open only after the first clusters pass quality, margin and retention gates.
Move toward 60,000 active members as a five-year capacity objective, not a launch forecast.
The Path
Stage-gated execution, not capital-first expansion
Every step has an evidence gate and a stop condition.
| Stage | Evidence required | Decision |
|---|---|---|
| 0 · Readiness | Licensing path, clinical scope, partner agreements, test-level costs | Approve capped pilot only |
| 1 · Paid pilot | 300–500 paid members; positive direct contribution; reliable quality | Refine or proceed to density |
| 2 · Density | Route economics, institutional contracts, cohort utilization | Add Bhaktapur replication |
| 3 · Renewal | Payment-backed renewal and controlled benefit use | Release Valley growth capital |
| 4 · Replication | Audited unit economics and mature governance | Consider cities beyond the Valley |
Business Model
Recurring Revenue Engine
Acquire one institutional partner → onboard thousands of end customers.
Unit Economics
Nepal Subscriber Model
Investor-Grade Financial Profile
Modelled for Kathmandu Valley pricing and cost base. Assumptions to be re-confirmed against launch-quarter actuals.
Five-Year Capacity Objective
Kathmandu · Patan · Bhaktapur
One contiguous market, expanded only when each operating gate is passed
Maximum staged capital framework, not an upfront requirement
Five-year active-member capacity objective
- — Central processing hub in Kathmandu serving all three cities
- — 60+ spoke collection points across Kathmandu, Patan and Bhaktapur
- — 800+ doctors, polyclinics and institutional channel partners
- — Corporate wellness, cooperative and hospital OPD tie-ups across the Valley
At NPR 4,500 realised annual price, 60,000 active members equals NPR 27 Cr subscription ARR before add-ons. This is arithmetic, not a forecast.
City Expansion
Valley-First, Then National Replication
Scale driven by repeatable operating playbooks, not excessive capex.
Full premium hub with dense spoke network
Light hub plus high-volume partner network
Efficient hub with doctor-led acquisition
Spoke-first franchise and referral model
Revenue by Tier
Investor Selects Speed of Scale
Capital size determines expansion velocity and ownership depth.
FY 2027 revenue ranges are modelled projections, not commitments.
| Tier | Capital | FY 2027 Revenue | Outcome |
|---|---|---|---|
| Entry Tier | NPR 1 Cr – 3 Cr | NPR 4 Cr – 8 Cr | Kathmandu validation + initial spoke activation |
| Growth Tier | NPR 5 Cr – 8 Cr | NPR 10 Cr – 18 Cr | Valley dominance across Kathmandu, Patan and Bhaktapur |
| Scale Tier | NPR 10 Cr – 15 Cr | NPR 20 Cr – 40 Cr | Multi-city rollout + Tier 1 and Tier 2 replication |
| Platform Tier | NPR 20 Cr+ | NPR 50 Cr+ | National infrastructure + insurance + enterprise scale |
Financial Outlook
Nepal Operations — Revenue Scenarios
Practical and Scalable Revenue Projections
Nepal entity only. India revenues are reported separately.
| Year | Base Case | Growth Capital | Platform Scale |
|---|---|---|---|
| FY 2026-27 | NPR 6 Cr | NPR 14 Cr | NPR 30 Cr |
| FY 2027-28 | NPR 12 Cr | NPR 32 Cr | NPR 65 Cr |
| FY 2028-29 | NPR 20 Cr | NPR 55 Cr | NPR 120 Cr |
Investor Confidence
Why Nepali Investors Engage
Revenue visibility precedes valuation expansion.
Strategic Value Drivers
What Builds Enterprise Value
Recurring Healthcare Ownership
The moat is recurring healthcare ownership.
| Traditional Nepali Labs | NanoChain Nepal |
|---|---|
| One-time test transactions | Preventive healthcare membership |
| Pricing competition | Annual recurring revenue model |
| Fragmented customer retention | Customer lifetime expansion |
| No subscription revenue | Institutional partnership channels |
| Low lifetime value | Scalable retention infrastructure |
Beyond Testing
Building the Next Layer of Enterprise Value
From diagnostics operator to data-driven preventive healthcare intelligence platform.
Value Creation Gates
From pilot evidence to a scalable platform
No valuation is asserted before paid demand, renewal and contribution economics are demonstrated.
How to Invest
Flexible Participation Structure
Invest based on your conviction, ownership preference and strategic alignment.
Strategic angels · Follow-on rights
Lead investors & syndicates · Board visibility
Institutional growth · Co-investment rights
Strategic partners · Board seat
Milestone-linked deployment · Structured for disciplined long-term capital alignment
The Thesis
Scalable · Recurring · Defensible · Investable
- — A predecessor operation demonstrated product interest and exposed the financial structures NanoChain must not repeat.
- — A 90-day paid Nepal pilot comes before network expansion.
- — NanoCard can create recurring revenue only if utilization, direct contribution and renewal are proven.
- — Dense collection routes and contracted institutional volume are operating gates, not assumptions.
- — Equity capital is released by milestones; high-cost unsecured debt and premature fixed overhead are avoided.
Founder & CEO · NanoChain · NanoCard